Seres Therapeutics (NASDAQ:MCRB) Shares Up 10% - Here's Why

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report)'s share price shot up 10% during mid-day trading on Tuesday . The company traded as high as $8.50 and last traded at $8.23. 57,425 shares were traded during trading, a decline of 64% from the average session volume of 160,625 shares. The stock had previously closed at $7.48.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Chardan Capital restated a "buy" rating and issued a $25.00 price objective on shares of Seres Therapeutics in a research report on Thursday, March 20th. The Goldman Sachs Group reduced their price target on Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating for the company in a report on Friday, March 14th. Finally, StockNews.com raised Seres Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $80.00.

Seres Therapeutics Stock Performance

The company has a market capitalization of $87.88 million, a price-to-earnings ratio of -43.82 and a beta of 2.54. The stock's 50-day moving average price is $12.99 and its 200-day moving average price is $15.18.

Institutional Trading of Seres Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Avantax Advisory Services Inc. boosted its position in shares of Seres Therapeutics by 170.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock worth $38,000 after buying an additional 28,500 shares in the last quarter. Jane Street Group LLC raised its position in Seres Therapeutics by 181.4% during the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock worth $49,000 after acquiring an additional 37,866 shares during the last quarter. Virtu Financial LLC lifted its holdings in shares of Seres Therapeutics by 44.8% in the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 18,191 shares in the last quarter. Northern Trust Corp grew its position in shares of Seres Therapeutics by 20.4% in the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company's stock valued at $218,000 after purchasing an additional 44,461 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Seres Therapeutics by 12.9% during the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company's stock worth $363,000 after purchasing an additional 43,700 shares in the last quarter. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.